- Home
- RY vs AZN Comparison
RY vs AZN Comparison
Compare RY & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RY | AZN |
|---|---|---|
| Founded | 1864 | 1992 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.4B | 285.7B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | RY | AZN |
|---|---|---|
| Price | $169.28 | $209.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $162.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 02-26-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.65% | 1.56% |
| EPS Growth | 25.07 | ★ 45.33 |
| EPS | ★ 10.04 | 6.54 |
| Revenue | $44,415,504,717.00 | ★ $58,739,000,000.00 |
| Revenue This Year | $16.04 | $8.76 |
| Revenue Next Year | $5.00 | $5.81 |
| P/E Ratio | ★ $16.88 | $31.43 |
| Revenue Growth | ★ 15.03 | 8.63 |
| 52 Week Low | $106.10 | $122.26 |
| 52 Week High | $176.19 | $206.71 |
Technical Indicators
Market Signals| Indicator | RY | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 88.00 |
| Support Level | $167.30 | $187.06 |
| Resistance Level | $176.19 | $193.97 |
| Average True Range (ATR) | 2.83 | 3.92 |
| MACD | -0.18 | 5.56 |
| Stochastic Oscillator | 39.77 | 99.56 |
Price Performance
Historical ComparisonAbout RY Royal Bank Of Canada
Royal Bank of Canada is one of the two largest banks in Canada, with around CAD 2.3 trillion in assets at the end of fiscal 2025. It is a diversified financial services company, offering personal and commercial banking, wealth management, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada and has dominant market shares. RBC also has wealth and capital market businesses in the US, UK, and other countries. RBC is a top 15 investment bank globally.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.